Our results seem to support the last hypothesis because a stronger PTH-rP-specific cytolytic response to prostate carcinoma LNCaP cells was observed in CTL lines derived from spleen cells taken from mice receiving the sequential GC90/IRIV/peptide treatment. This evidence concerns the gene BLOC1S3 and prostate carcinoma.